| 3301 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3302 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
36 |
| 3303 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
61 |
| 3304 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
11 |
| 3305 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome |
Hematology |
2022 |
Standard Therapy |
Germany |
61 |
| 3306 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome – Raeb2 |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3307 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome Rc |
Hematology |
2022 |
Standard Therapy |
Poland |
3 |
| 3308 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Excess Blasts 1 |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3309 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Excess Blasts 2 |
Hematology |
2022 |
Standard Therapy |
Poland |
67 |
| 3310 |
Apheresis |
Allogeneic |
Myelodysplastic Syndrome With Fibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3311 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3312 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3313 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
57 |
| 3314 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3315 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3316 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
67 |
| 3317 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3318 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3319 |
Apheresis |
Allogeneic |
Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
60 |
| 3320 |
Apheresis |
Allogeneic |
Myelofibrosis Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
69 |
| 3321 |
Apheresis |
Allogeneic |
Myelofibrosis Post Essential Thrombocythemia |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3322 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3323 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3324 |
Apheresis |
Allogeneic |
Myelofibrosis With Myeloid Metaplasia |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3325 |
Apheresis |
Autologous |
Myeloma |
Hematology |
2022 |
Standard Therapy |
Germany |
54 |
| 3326 |
Apheresis |
Allogeneic |
Myeloma Multiplex |
Hematology |
2022 |
Standard Therapy |
Poland |
31 |
| 3327 |
Apheresis |
Allogeneic |
Myeloproliferative Neoplasms With Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
59 |
| 3328 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
50 |
| 3329 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
37 |
| 3330 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3331 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3332 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
21 |
| 3333 |
Apheresis |
Allogeneic |
No Data |
Hematology |
2022 |
Standard Therapy |
Poland |
38 |
| 3334 |
Apheresis |
Autologous |
Nodular Lymphocyte Predominant Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
31 |
| 3335 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
73 |
| 3336 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
61 |
| 3337 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
53 |
| 3338 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
18 |
| 3339 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
28 |
| 3340 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
55 |
| 3341 |
Apheresis |
Allogeneic |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3342 |
Apheresis |
Autologous |
Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
52 |
| 3343 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3344 |
Apheresis |
Allogeneic |
Osteomyelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3345 |
Apheresis |
Allogeneic |
Other Immune System |
Hematology |
2022 |
Standard Therapy |
Poland |
46 |
| 3346 |
Apheresis |
Allogeneic |
Other Malignancy |
Hematology |
2022 |
Standard Therapy |
Poland |
72 |
| 3347 |
Apheresis |
Allogeneic |
Peripheral T-Cell Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
32 |
| 3348 |
Apheresis |
Allogeneic |
Plasma Cell Disorder |
Hematology |
2022 |
Standard Therapy |
Poland |
56 |
| 3349 |
Apheresis |
Allogeneic |
Plasma Cell Leukemia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3350 |
Apheresis |
Allogeneic |
Post-Essential Thrombocythemia-Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
64 |
| 3351 |
Apheresis |
Allogeneic |
Post–Polycythemia Vera Myelofibrosis (Post-Pv Mf) |
Hematology |
2022 |
Standard Therapy |
Poland |
48 |
| 3352 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
65 |
| 3353 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
65 |
| 3354 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
58 |
| 3355 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
39 |
| 3356 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
67 |
| 3357 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
37 |
| 3358 |
Apheresis |
Autologous |
Primary Central Nervous System Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
69 |
| 3359 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
62 |
| 3360 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
66 |
| 3361 |
Apheresis |
Allogeneic |
Primary Myelofibrosis |
Hematology |
2022 |
Standard Therapy |
Poland |
70 |
| 3362 |
Apheresis |
Allogeneic |
Primary Refractory T-Cell Lymphoma |
Hematology |
2022 |
Standard Therapy |
Poland |
55 |
| 3363 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Poland |
58 |
| 3364 |
Apheresis |
Allogeneic |
Secondary Acute Myeloid Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
51 |
| 3365 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2022 |
Standard Therapy |
Poland |
53 |
| 3366 |
Apheresis |
Allogeneic |
Severe Aplastic Anemia |
Hematology |
2022 |
Standard Therapy |
Poland |
45 |
| 3367 |
Apheresis |
Allogeneic |
Severe Combined Immunodeficiency |
Hematology |
2022 |
Standard Therapy |
Poland |
3 months |
| 3368 |
Apheresis |
Allogeneic |
Sezary Syndrome |
Hematology |
2022 |
Standard Therapy |
Poland |
59 |
| 3369 |
Apheresis |
Allogeneic |
T-Cell Acute Lymphoblastic Leukemia |
Hematology |
2022 |
Standard Therapy |
Poland |
6 |
| 3370 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
37 |
| 3371 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
30 |
| 3372 |
Apheresis |
Allogeneic |
T-Cell Lymphoblastic Leukemia |
Hematology |
2022 |
Standard Therapy |
Germany |
46 |
| 3373 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
52 |
| 3374 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
51 |
| 3375 |
Apheresis |
Allogeneic |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
52 |
| 3376 |
Apheresis |
Autologous |
T-Cell Non-Hodgkin Lymphoma |
Hematology |
2022 |
Standard Therapy |
Germany |
60 |
| 3377 |
Apheresis |
Autologous |
Testicular Cancer |
Hematology |
2022 |
Standard Therapy |
Germany |
48 |
| 3378 |
Apheresis |
Allogeneic |
Thalassemia Major |
Hematology |
2022 |
Standard Therapy |
Poland |
15 |
| 3379 |
Adipose Tissue |
Autologous |
Gonarthrosis |
Orthopedy |
2022 |
Experimental Therapy |
Poland |
60,11 |
| 3380 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2022 |
Experimental Therapy |
Poland |
41,9 |
| 3381 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2022 |
Experimental Therapy |
Poland |
30,1 |
| 3382 |
Adipose Tissue |
Autologous |
Internal Damage To The Knee Joint |
Orthopedy |
2022 |
Experimental Therapy |
Poland |
53 |
| 3383 |
Skeletal Muscle |
Allogeneic – Related |
Duchenne Muscular Dystrophy (DMD) |
Genetic disorder |
2021 |
Experimental Therapy |
Poland |
7 |
| 3384 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Graft Versus Host Disease |
Hematology |
2021 |
Experimental Therapy |
Poland |
7,8 |
| 3385 |
Cord Tissue |
Allogeneic – Unrelated |
Acute Myeloid Leukemia – Transplantation Failure |
Hematology |
2021 |
Experimental Therapy |
Poland |
13,5 |
| 3386 |
Cord Tissue |
Allogeneic – Unrelated |
Ags (Autism + Epilepsy) |
Neurology |
2021 |
Experimental Therapy |
Poland |
13,3 |
| 3387 |
Cord Tissue |
Allogeneic – Unrelated |
Ags (Autism + Epilepsy) |
Neurology |
2021 |
Experimental Therapy |
Romania |
13 |
| 3388 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
74,4 |
| 3389 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
64,11 |
| 3390 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
70,11 |
| 3391 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
59,2 |
| 3392 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
47,9 |
| 3393 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |
| 3394 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |
| 3395 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
66,8 |
| 3396 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Experimental Therapy |
Poland |
28,4 |
| 3397 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |
| 3398 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |
| 3399 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |
| 3400 |
Cord Tissue |
Allogeneic – Unrelated |
Amyotrophic Lateral Sclerosis |
Neurology |
2021 |
Clinical Trial ALSTEM |
Poland |
no data |